# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Drug-device combination leverages Biora's NaviCap™ platform to deliver tofacitinib directly to colonic tissue as a potentia...
-SEC Filing
-SEC Filing-SEC Filing
Biora Therapeutics, Inc. (NASDAQ:BIOR), the biotech company that is reimagining therapeutic delivery, today announced that it w...